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Abstract
While bone marrow (BM)-derived cells have been comprehensively studied for their pro-
pitious pre-clinical results, clinical trials have shown controversial outcomes. Unlike pre-
viously acknowledged, more recent studies have now confirmed that humoral and para-
crine effects are the key mechanisms for tissue regeneration and functional recovery, in-
stead of transdifferentiation of BM-derived cells into cardiovascular tissues. The pro-
gression of the understanding of BM-derived cells has further led to exploring efficient 
methods to isolate and obtain, without mobilization, sufficient number of cell populations 
that would eventually have a higher therapeutic potential. As such, hematopoietic CD31+
cells, prevalent in both bone marrow and peripheral blood, have been discovered, in re-
cent studies, to have angiogenic and vasculogenic activities and to show strong potential 
for therapeutic neovascularization in ischemic tissues. This article will discuss recent ad-
vancement on BM-derived cell therapy and the implication of newly discovered CD31+
cells.
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INTRODUCTION
Cardiovascular diseases are major morbidity and mortality 
in the industrialized countries. In the United States, ischemic 
cardiovascular diseases are the number one cause of death 
[1]. Although numerous pharmacological and surgical thera-
pies have been developed, many of the patients still exhibit 
grave symptoms and continue to show increasing heart fail-
ure or advance critical limb ischemia and the need for hospi-
talization [2-4]. Due to our limited therapeutic options, the 
demand for novel methods of treatment for ischemic car-
diovascular diseases has been increasing. One of the major 
causes of ischemic cardiovascular diseases is atherosclerosis. 
This leads to the blocking of the blood vessels, which, in 
turn, needs a new vascular growth for the affected tissues 
to prevent or reverse disease progression. Endothelial cells 
are a major component of blood vessels and, thus, are essential 
for vascular growth; therefore, the treatment of ischemic 
cardiovascular diseases should primarily aim neovasculariz-
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ation through endothelial cells.
The notion of stem cells has attracted much attention 
due to their potential to develop new tissues. Although ethi-
cally controversial, embryonic stem cells (ESCs) have shown 
promising potential for tissue regeneration; therefore, ESCs 
have been extensively studied for cardiovascular regener-
ation in animal models for the past decade. On the contrary 
to their vast potential, ESCs trigger host immune response 
to allogeneic ESCs [5], have shown the risks of teratoma 
formation [6], and need to be ethically solved before clinical 
translation. Thus, induced pluripotent stem cells (iPSCs) have 
been discovered to circumvent such issues [7, 8]. iPSCs, 
however, still have many questions to answer regarding its 
benefits and impediments [9-13].
In addition, adult stem or progenitor cells have shown 
promising outlooks in treating cardiovascular diseases, espe-
cially bone marrow (BM)-derived cells. This discovery has 
led to a wider approach to cell therapy. BM-derived cells 
have shown regenerative effects in both preclinical studies 
and clinical trials. Because of their suggestive results, BM-de-
rived cells have been widely investigated, particularly 
BM-derived mononuclear cells (MNCs), endothelial progeni-
tor cells (EPCs), or mesenchymal stem cells (MSCs). BM-de-
rived EPCs have displayed therapeutic potentials in my-
ocardial and peripheral vascular ischemia in animal models 
[14-21] and positive results in a series of clinical trials using 
EPCs or similar BM cells to treat post-MI cardiac dysfunction 
and critical limb ischemia [22-34]. Contrarily, in other stud-
ies, BM-derived MNCs exhibited contradictory results in 
a similar subset of patients with myocardial ischemia [35-38]. 
As more clinical trials with MNCs, early EPCs, MSCs, and 
CD34+ cells are underway, more agreeable conclusion will 
be drawn in the near future.
Advances and expansions have been made involving ther-
apeutic effects of BM-derived stem and progenitor cells. 
Formerly, transdifferentiation into vasculature and/or car-
diomyocytes was thought to be the predominant mechanism 
responsible for cardiac regeneration or repair [17, 20, 21, 
39-47]; however, recent studies exposed such notions were 
overestimated [48-50] and that humoral or paracrine effects 
are the main mechanisms. The humoral mechanism benefits 
regeneration or restoration of myocardium and peripheral 
vascular tissues by inducing neovascularization, protecting 
ongoing cell apoptosis and degeneration, and promoting re-
generation of endothelial cells, cardiomyocytes, and smooth 
muscle cells through soluble factors or cell-to-cell contact 
[42, 51-58]. Numerous attempts to identify the soluble factors 
responsible for paracrine effects of MSCs led to discovering 
secreted frizzled related protein 2 (Sfrp2), an antagonist of 
Wnt signaling [59], which had a dose-dependent cytopro-
tective effect, with its concentrations up to 15 nM, in in 
vitro caspase activity assay. Additionally, in their follow-up 
study, the exogenous delivery of Sfrp2 to rat hearts, at ther-
apeutic doses of 4 μg per heart, improved cardiac function 
in experimental MI [60].
Furthermore, the search of effector cells, using their mark-
ers that are not specific only to stem or progenitor cells, 
has led to the discovery of CD31+ cells, representing a sub-
population of BM- and peripheral blood (PB)-derived MNCs. 
These CD31+ cells were discovered to have higher angiogenic 
and vasculogenic activities and efficient neovascularization 
in hindlimb ischemia [61, 62]. Hence, based on this in-
formation, this review will cover the characteristics and 
possibilities of EPCs, BM-MNCs, and recently identified 
CD31+ cells.
ENDOTHELIAL PROGENITOR CELL (EPC)
Base on the idea that endothelial cells are major compo-
nents in maintaining vascular homeostasis and in patho-
genesis of a variety of diseases, endothelial cells have been 
explored and BM-derived circulating progenitor cells or an-
gioblasts in human peripheral blood (hPB) have been dis-
covered [63]. Because these cells had properties like endothe-
lial cells (ECs) and could differentiate into ECs, BM-derived 
circulating progenitor cells were referred as EPCs. Based 
on the notion that BM-derived circulating progenitor cells 
contribute to blood vessel growth, Asahara and colleagues 
suggested the groundbreaking concept of postnatal vasculo-
genesis by showing that EPCs were incorporated into the 
vasculature in adult animals and formed new vessels in ische-
mic models [39]. In addition, the transplantation of EPCs 
was able to induce neovascularization and assist ischemic 
limb repair [14]. The concept of postnatal vasculogenesis 
has been widely accepted; however, due to the lack of specific 
markers and to diverse phenotypes, an accurate and precise 
identification of EPCs has not been confirmed, yet. In addi-
tion, the advance of technologies allowed the identifying 
of the role of EPCs in disease pathogenesis [64-67] besides 
a normal component of the formed elements of circulating 
blood [68].
1. Early EPC
Due to the lack of specific surface markers on EPCs, various 
BM cell fractions were short-term cultured in endothelial 
differentiation media to enrich EPCs. For example, CD133, 
which is displayed on immature hematopoietic stem cells 
(HSCs), was used for culture derivation of EPCs [69]. On 
the other hand, for therapeutic purposes, the total MNC 
population, which has been widely used to obtain EPCs, 
was short-term cultured for 4–7 days on vitronectin- or 
fibronectin-coated dishes and the attached, or adherent, cells 
were used as EPCs, though not all of the cells collected 
were considered EPCs [14, 39, 63, 70, 71]. These cells ex-
pressed endothelial-like characteristics by the uptake of ace-
tylated low-density lipoproteins, the binding of lectins, the 
expression of several EC-specific proteins (VEGFR-2, Tie2, 
vascular endothelial [VE]-cadherin, von Willebrand factor, 
endothelial nitric oxide synthase [eNOS], and CD146), and 
a low proliferation rate. On the contrary, other studies have 
refuted the endothelial-like characteristics of EPCs because 
these cells also displayed monocyte/macrophage markers, 
such as CD45, CD11b, and CD11c [54, 72-74]. Recent studies 
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have also, instead, referred these cells as angiogenic cells 
[74], for they contribute more to vessel formation through 
angiogenic effects rather than form ECs in vivo. EPCs are 
able to incorporate into the neovasculature and differentiate 
into ECs [20, 39, 63]. Also, Wang et al. [75] postulated that 
EPC containing cell population is inherently multipotent 
and may include smooth muscle progenitor cells. Additio-
nally, other studies pointed that EPCs were able to differ-
entiate into cardiomyocytes and smooth muscle cells in 
mouse [47] and rat [17, 21] models of MI; peripheral EPCs, 
mobilized by granulocyte-colony stimulating factor (G-CSF) 
administration and myocardial ischemia, have displayed car-
diac-, muscle-, liver-, and neural-lineage markers [76, 77]. 
However, this evidence of extra-endothelial transdiffer-
entiation is sporadic and not widely accepted after the origi-
nal publications.
In one study, EPCs have been shown to transdifferentiate 
by fusing with cells of different lineage, such as newly formed 
cardiomyocytes in mice, administered with human EPCs, 
contained both human and mouse X-chromosomes [78]. 
However, only 3% of the ECs displayed any evidence of 
human-mouse cell fusion. In addition, most studies have 
shown little or no evidence of fusion between EPCs and 
cells of different lineages. In most recent studies, the trans-
differentiation of EPCs has been shown to be possible but 
not prevalent.
Expression of certain factors and molecules, such as eNOS 
and inducible nitric oxide synthase (iNOS), which increase 
circulation by dilating capillaries [42], and pro-angiogenic 
and anti-apoptotic growth factors (i.e. hepatocyte growth 
factor [HGF], insulin-like growth factor 1 [IGF-1], and 
VEGF) [51], is one of the ways that EPCs contribute to 
tissue regeneration and preservation. The release of certain 
growth factors causes the recruitment of EPCs around the 
ischemic area [52] and, in turn, stimulates the cells to pro-
liferate, migrate, and maintain the survival of EPCs and 
pre-existing mature endothelial cells [79].
In earlier studies, EPCs were often administered systemati-
cally; however, in recent studies, due to the low rate of 
retention, cells have been transplanted or injected directly 
onto the affected area. Transplantation of EPCs [14, 16, 20, 
80, 81] facilitated neovascularization in animal models of 
acute myocardial ischemia, and analogous effects in humans 
[30, 82, 83].
2. Late EPC
Late EPCs, or endothelial colony-forming cells (ECFCs), 
were discovered from circulating MNCs that were collected 
after more than 2 weeks in conventional EPC culture. These 
cells may be cultured variably; however, they commonly 
have round morphology, fast cell proliferation rate, and ex-
press similar surface markers (EC makers) [73, 84]. ECFCs 
need to be studied much further and their culture systems 
developed more before any application to therapeutic or 
regenerative use, because they were able to neither convinc-
ingly show paracrine effects nor show vasculogenic effects 
without MatrigelTM plug assay [84, 85]. ECFCs’ capability 
to differentiate into ECs and their regenerative and ther-
apeutic effects on vasculature in ischemia need to be 
troubleshot. Furthermore, because there is no defined line 
between ECFCs and ECs, the possibilities that these cells 
are primitive circulating ECs or are ECs sloughed off from 
vessels still remain to be established.
HEMATOPOIETIC STEM CELLS (HSCs)
HSCs are multipotent stem cells that have the capacity 
to give rise to all blood cell types, to commit to lymphoid 
lineages, and to self-renew [86]. In adult vertebrates, HSCs 
occupy < 1% of the total BM cells and constitute 1:10,000 
cells in the myeloid tissue. Hematopoietic tissues contain 
cells in the long- and short-term regenerative capacities and 
committed multipotent, oligopotent, and unipotent progeni-
tors. Currently, HSCs are one of the best characterized stem 
cells, due to their lack of markers indicating lineage commit-
ment (lin-) and to the presence of combination of indicating 
markers, such as CD133, CD34, CD38, CD90 (Thy1), CD105, 
and CD117 (c-kit) [87-89].
 HSCs have been applied for the treatment of hematologic 
diseases for over three decades. Furthermore, due to their 
multipotency, HSCs were applied for the regeneration of 
damaged myocardium [45, 46]. In these studies, HSCs were 
shown to be able to transdifferentiate into nonhematopoietic 
cells, such as cardiomyocytes, ECs, and vascular smooth mus-
cle cells in infarcted heart [45, 46]. However, some studies 
have refuted that HSCs, represented by lin-negative, sca1-po-
sitive, and c-kit-positive, do not transdifferentiate into any 
cardiomyocytes, after transplantation, in a mouse MI model 
[48, 49]. While no other specific human HSCs have been 
used, human CD34+ [17, 27, 47, 90] and CD133+ cells [91-93] 
were used in experiments reporting that post-MI cardiac 
function has been improved, conversely, through non-car-
diomyogenic effects. The need for the use of mobilizing 
cytokines, such as G-CSF, to collect sufficient amount of 
CD34+ or CD133+ cells expenses high cost for clinical appli-
cation and may result in a risk to patients. 
BM MONONUCLEAR CELLS (BM-MNCs)
BM-MNCs are composed of a number of different types 
of cells, such as hematopoietic cells, fibroblasts, osteoblasts, 
myogenic cells, and endothelial-lineage cells [94]. BM-MNC 
transplantation facilitated neovascularization in animal mod-
els of acute myocardial ischemia [94, 95] and similar results 
in humans [96-99]. Because the monocyte/macrophage pro-
portion of BM-MNCs expresses key angiogenic growth fac-
tors and cytokines (e.g., VEGF, basic fibroblast growth factor 
[FGF2], angiopoietin-1 [Ang-1], interleukin [IL]-1β, tumor 
necrosis factor-α [TNF-α]) and stimulates angiogenesis [94, 
100, 101], this cocktail of angiogenic factors mixed in the 
population may cause paracrine effects that stimulate pro-
liferation, homing, and differentiation of preexisting stem 
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cells [102].
On the contrary to some of the beneficial effects exerted 
by BM-MNCs, lymphocytes and monocytes/macrophages ex-
press pro-inflammatory cytokines, such as IL-1, IL-2, IL-6, 
IL-12, interferon-γ (IFN-γ), lymphotoxin, and tumor necrosis 
factors (TNFs) [103-105], and may cause negative inotropic 
effect on myocardium. Also, because lymphocytes and mono-
cytes/macrophages, which are inflammatory cells, are a large 
portion of the MNC population, myocardial damage after 
MI may be accelerated by these cells as well as severe hemor-
rhage or inflammation, instigated by the transplanted MNCs, 
could jeopardize the survival and transdifferentiation of 
transplanted MNCs [17].
NON-TRANSDIFFERENTIATION THERAPEUTIC 
EFFECTS OF BM-DERIVED CELLS
The plasticity, true tissue generation, or transdifferen-
tiation capacity of BM-derived cells has been widely debated, 
despite promising therapeutic potential [48-50]. Many recent 
studies suggest that the paracrine mechanism is the primary 
mechanism that accounts for therapeutic effects in car-
diovascular diseases, not vasculogenesis or exogenous myo-
genesis because vasculogenesis and exogenous myogenesis 
rarely occur. BM cells release angiogenic factors VEGF, 
Chemokine (C-C motif) ligand 2, (CCL2, also known as 
MCP-1), FGF2, Angpt1, and Wnt [94, 106, 107]. It was 
reported that Wnt signaling mediate angiogenic effects of 
human fetal CD133+ cells on ischemic wounds [107] and 
that these growth factors stimulate angiogenesis, prevent 
tissue apoptosis or necrosis, and induce endogenous resident 
stem cell migration and proliferation via paracrine response 
[51, 55, 57, 58, 107, 108]. Recent studies reported that humor-
al effects can be attributed to both implanted cells and the 
target host tissues receiving the cell therapy [52, 108, 109]. 
Although fusion as a mechanism for transdifferentiation is 
well known [110, 111], unlike earlier studies [112, 113], 
recent studies have discovered that fusion is minimally in-
volved in phenotypic changes of stem cells [58].
HEMATOPOIETIC CD31+ CELLS
1. Role of CD31 in vascular biology
CD31, also known as platelet endothelial cell adhesion 
molecule (PECAM)-1, is a 130-kDa transmembrane protein 
consisting of six extracellular immunoglobulin folds. In its 
cytoplasmic domain, there are two immunoreceptor ty-
rosine-based inhibitory motifs (ITIM) for interactions with 
signaling molecules. CD31 is expressed on the cell surface 
of ECs and hematopoietic cells, such as monocytes, platelets, 
neutrophils, natural killer cells, megakaryocytes, and some 
T cells. CD31 mediates homotypic adhesion between adjacent 
ECs as well as between ECs and leukocytes [114, 115]. A 
role of CD31 in migration through ECs has also been reported 
for neutrophils and monocytes [116], and subsequently for 
numerous other cell types, including natural killer cells [117], 
hematopoietic progenitor cells (HPCs) [118] and certain sub-
sets of lymphocytes [119, 120].
Cell-cell and cell-extracellular matrix interactions are two 
of the essential roles during blood vessel formation and 
regression. CD31 has been gaining attention as it is being 
recognized to suppress cell death through interactions, such 
as homophilic interactions of CD31 that are in between 
ECs and monocytes [121]. The interaction of CD31 in sup-
pressing apoptosis suggests that CD31 releases pro-survival 
signals, and the interaction also has been reported to induce 
Akt, a serine/threonine protein kinase, phosphorylation. On 
the contrary to apoptosis suppression characteristics, CD31 
also assist ECs in apoptosis through metalloproteinase- de-
pendent cleavage and caspase-mediated cleavage of the cyto-
plasmic tail [122].
Additionally, given that it is expressed abundantly in ECs, 
CD31 has been shown to be involved in the initial stabiliza-
tion and formation of cell-cell contacts at lateral junctions 
of ECs, the maintenance of a vascular permeability barrier, 
modulation of cell migration, transendothelial migration of 
monocytes and neutrophils, and formation of blood vessels 
in angiogenesis [114, 116, 123, 124]. Moreover, earlier studies 
have shown that CD31 formed a functional complex with 
cadherin 5, β-catenin, and F-actin to control EC tube for-
mation [125]. However, a later study showed that CD31 
was involved in the adhesion/signaling events necessary for 
the migration of ECs and subsequent tube formation during 
angiogenesis, independent of VE-cadherin [126].
2. Identification of specialized multimodal angio-vasculogenic 
cells
To advance cell therapy, it seems very crucial to target 
and identify cells that are specialized for humoral effects, 
since recent studies almost universally reported that the ma-
jor therapeutic mechanism of BM-derived stem or progenitor 
cells is humoral or paracrine effect [52, 55-57]. Therefore, 
recent studies have used specific surface markers to isolate 
cells enriched in humoral activities from BM and/or PB 
[61, 62]. Using surface makers allows the cells to be isolated 
without cell culture, which saves costs, and safely evading 
any harmful effects that may come with using animal serum. 
In a series of studies, CD31 was used as a marker to find 
BM-derived cells that have multimodal effects, such as angio-
genic, vasculogenic, higher adhesion, and almost exclusive 
hematopoietic stem/progenitor cell activities (Fig. 1).
3. Angiogenic activities
Based on genome-wide gene expression analyses of mouse 
BM (mBM), human BM (hBM), and hPB, angiogenic genes 
were enriched in CD31+ cells when compared with CD31− 
cells [61, 62]. Compared to their negative counterparts, 
hBM-CD31+ cells expressed higher levels of heparin-binding 
EGF-like growth factor (HBEGF), which is active in vascular 
smooth muscle cell recruitment [127] and IL-8, a macro-
phage-derived mediator of angiogenesis [128]; mBM-CD31+ 
cells expressed high levels of Angpt-1, an eminent angiogenic 
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Fig. 1. The multimodal effects of 
BM-derived hematopoietic CD31+
cells. BM-derived CD31+ cells 
highly expressed pro-angiogenic 
genes (angiogenicity). BM-derived
CD31+ cells showed a high num-
ber of EPCs and formed a tubular 
structure (vasculogenicity). The 
high adhesion capacity and low 
inflammatory activity of the cells 
allowed high engraftment and 
mild inflammation, respectively. 
The hematopoietic stem and pro-
genitor cells were enriched in 
CD31+ cells (HSC and HPC activ-
ity) [61, 62].
growth factor [129, 130], and GATA2, a transcription factor 
that proliferates angiogenesis when activated [131]. Similar-
ly, hPB-CD31+ expresses extremely high levels of neuro-
pilin-1 (NRP1), which is a necessity in vascular development 
and a mediator in VEGF-dependent angiogenesis [132], com-
pared with the negative cells.
4. Vasculogenic properties
The recurring questions that need to be addressed are 
whether hematopoietic cells can give rise to ECs [46, 133, 
134] and what is the true identity of those cells. A majority 
of studies, including ours, have demonstrated that BM-de-
rived cells can generate ECs. On the other hand, several 
studies have refuted such notion [48, 50, 135] by using MI 
models to prove vasculogenic effects [48, 49]. However, those 
refutations are inappropriate since a MI model accepts mini-
mal amount of engraftment from any cell, including BM-de-
rived cells. Other studies supported our notion that the re-
tention of ESC-derived cardiomyocytes or cardiac stem or 
progenitor cells was minimal in a MI model as well [136-138]. 
MI hinders engraftment and survival of any implanted cells, 
such as constant motion of the heart, inflammation in acute 
stages of infarction, insufficient oxygen and nutrients, and 
tight junctions between cardiomyocytes. One study reported 
that it is common for EC transdifferentiation to occur in 
transplanted heart samples [139]. In other independent stud-
ies, with the correct conditions, such as suitable BM-derived 
cells with permissive models, BM-derived cells can give rise 
to ECs [140, 141]. Based on the results of these studies, 
cell types and/or environment is very crucial to generating 
ECs from BM or PB cells.
In recent studies on the vasculogenic effects of CD31+ 
cells [61, 62], compared with CD31− cells, mBM-, hBM-, 
and hPB-CD31+ cells gave rise to a large number of EPCs 
in culture and expressed EC-specific markers, such as von 
Willebrand factor, VEGFR-2, VE-cadherin, and CD31. In 
addition, hPB-CD31+ cells formed aggregates and, sub-
sequently, underwent tubular structural changes within the 
round cell cluster by day 10 followed by the formation of 
complete linear tubular structure that mimicked in vivo 
vasculogenesis. This linear tubular structure had stained pos-
itive for lectin and took up acetylated human low-density 
lipoprotein, indicating EC characteristics. In vivo vasculo-
genesis studies had also been investigated. By using a mouse 
model of hindlimb ischemia, vasculogenic activities of CD31+ 
cells had been tested [61, 62]. However, due to the divisive 
notion of transdifferentiation potential of BM cells [48, 50, 
54, 134, 140, 141], the confirmation methods used were 
rigorous and definitive: confocal microscopy with 3D re-
construction of multiple images were used to clearly demon-
strate that a fraction of CD31+ cells were colocalized with 
the ECs within the vascular structure even up to 8 weeks 
after; flow cytometric analysis of enzymatically digested hin-
dlimb tissues showed that up to 4% of the ECs in the ischemic 
tissues were derived from transplanted mBM- or hPB-CD31+ 
cells; fluorescent in situ hybridization of the digested tissues 
further confirmed the contribution of hPB-CD31+ cells into 
ECs [62]. This clear adaptation of definitive methods were 
the first to prove transdifferentiation of hematopoietic cells. 
Clearly, this experiment had proved that directly injected 
CD31+ cells give rise to functional ECs in ischemic tissues.
5. Higher adhesion and engraftment potential 
Low retention of injected cells is one of the major problems 
that hinder the therapeutic effects of cell therapy because 
a stable engraftment and a steady survival are needed for 
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optimal cell therapy. Studies reported that less than 25% 
of engraftment of transplanted neonatal cardiomyocytes 
were present within 24 hrs of MI in animal models [142] 
and, similarly, only 5% of CD34+ injected cells remained 
after 1 hr in human patients with MI [143]. Additionally, 
a majority of the directly injected, cultured early EPCs in 
myocardium post-MI had disappeared within a week [52]. 
Cell adhesion is also another crucial factor that can increase 
survival. Cells that adhere to extracellular matrix have higher 
chance of survival since they are able to avoid anoikis, an 
apoptosis caused by the lack of adhesion to extracellular 
matrix. CD31 was first found as an adhesion molecule [115, 
144] and had been shown to mediate cell-cell interaction 
via hemophilic interactions between CD31-expressing cells 
[145]. Genome-wide gene expression data showed high levels 
of genes relevant to adhesion, chemokine production and 
reception, and extracellular matrix in CD31+ cells [62]. 
Furthermore, cell adhesion assay showed that CD31+ cells 
have the capacity to adhere to more matrix proteins, such 
as fibronectin, collagen, laminin, and vitronectin [61, 62], 
than CD31− cells can. In vivo samples analyzed by the con-
focal microscopy and FACS analysis confirmed higher en-
graftment and survival of injected CD31+ cells compared 
to the CD31− cells or MNCs.
Although CXCR4/SDF-1 is a recognized signaling axis to 
mediate cell engraftment and migration, the engraftment 
of CD31+ cells do not depend on this axis because, when 
the levels of CXCR4 were measured, there was no difference 
in the expression between CD31+ and CD31− cells. On the 
other hand, CD31 molecules and other adhesion molecules, 
ICAM4 and integrin α, which were expressed more in CD31+ 
cells than CD31− cells, could have been involved in the 
higher engraftment of CD31+ cells. The higher engraftment 
of CD31+ cells would allow mBM- and hPB-CD31+ cells 
to increase angiogenic and vasculogenic capabilities.
6. Enriched HSCs & hematopoietic progenitor cells (HPCs)
According to the gene expression studies, hematopoietic 
stem and progenitor cell gene levels were reported to be 
higher in mBM-CD31+ cells and in hBM-CD31+ cells than 
in their corresponding negative cells, suggesting that more 
hematopoietic stem and progenitor cells are expected to be 
found in CD31+ cell population. Concurrent with this hy-
pothesis, according to in vitro colony-forming assay and 
in vivo BM cell transplantation, hematopoietic stem and 
progenitor cells are almost exclusively found in mBM-CD31+ 
cells; also, more than 90% of HSCs, multipotent progenitor 
cells, common lymphoid progenitor cells, and common mye-
loid progenitor cells in mBM express CD31 [61]. Similarly, 
in humans, CD31 was expressed in 99.8% of CD34+CD133+ 
and 89% of CD34+CD133− hBM cells, and clonogenic HPCs 
are found in hPB-CD31+ cells [62]. These findings suggest 
that HSCs and HPCs are heavily enriched in the CD31+ 
cell population.
There is some possibility that HSCs or HPCs included 
in the CD31+ population could have played a role in ischemic 
tissue repair because CD34+ cells, which include most HSC 
and EPCs, were known to be effective for treating ischemic 
cardiovascular diseases in animal models and human patients. 
Since the therapeutic effects of hBM-CD34−CD31+ cells and 
hBM-CD34+ cells were reported to be similar in improving 
mouse limb ischemia, it is more likely that non-HSCs could 
play a significant role in improving limb ischemia and/or 
therapeutic neovascularization.
CLINICAL APPLICATION
CD31 is the first marker that was used to isolate BM 
or PB cell subpopulation based on recent discovery on the 
mechanisms. With such isolation methods, cell mobilization 
can be avoided, and more effective, safe, and promising cell 
therapy can be developed to treat patients with advanced 
ischemic cardiovascular diseases. Approximately 30–35% of 
the total MNCs from hPB are CD31+ cells, which make 
them a better selection over either CD34+ or CD133+ cells 
[146, 147]. Due to such characteristics, the use of mobilizing 
agents, such as G-CSF, is not required for CD31+ cell collec-
tion [26, 146]. Moreover, unlike cultured EPCs or MSCs, 
CD31+ cells do not need cell culture, which can develop 
harmful side effects. The current cell culture condition of 
EPCs and MSCs use fetal bovine serum that may develop 
the risk of disease transmission through viral, prion, and 
zoonose contamination or immunological effects [148]. 
Similarly, the uncultured BM-derived MNCs or unfrac-
tionated cells are deemed inferior to CD31+ cells, because 
BM-derived MNCs include unnecessary cells that have po-
tential risks, such as calcification [149] and aggravation of 
ischemia [150], while no such adverse effects have been 
reported in CD31+ cells [61, 62]. Therefore, after having 
isolated CD31+ cells from nonangiogenic and highly in-
flammatory CD31− cells, CD31+ population can be utilized 
for higher therapeutic uses with smaller risks.
CONCLUSION
More investigation is needed to identify more angiogenic 
and/or vasculogenic cells for better efficiency and potency, 
since CD31+ cell population is heterogeneous, including T 
and B lymphocytes and myelomonocytic cells. Since CD31+ 
cells have been proven experimentally, the following studies 
should be clinical trials, starting with patients with critical 
limb ischemia or non-healing wounds. Also, since peripheral 
tissues provide more room for engraftment and less hostile 
environment for survival, critical limb ischemia should be 
an optimal introductory target to treat with CD31+ cells. 
Furthermore, with success, cell therapy with CD31+ cells 
could be expanded to treating other ischemic cardiovascular 
diseases, such as MI and stroke. 
After a decade of investigating and experimenting different 
perspectives of cell therapy, the importance of humoral and 
paracrine mechanism, host environment in cell engraftment 
and therapeutic effects, and selected cells has been discovered 
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and such knowledge has caused us to rethink and revamp 
our approach to cell therapy. If tissue generation from trans-
planted cells is not needed, instead of using stem or progenitor 
cells that are few and require much handling, using speci-
alized angiogenic and/or vasculogenic effector cells and tail-
ored treatment based on specific diseases should be the next 
aim in therapeutic effects. 
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